LOCATIONS: NEW YORK CITY | LONG ISLAND
BOOK YOUR CONSULTATION NOW: 917-261-7370
Explore personalized, evidence-based depression treatment options for Brooklyn residents seeking care nearby. Eligible patients may receive insurance coverage for SPRAVATO® and other covered behavioral health services.
NY Ketamine Infusions provides medically supervised treatment from our Lower Manhattan clinic at 160 Broadway, 16th Floor, New York, NY 10038, serving patients from Brooklyn Heights, DUMBO, Downtown Brooklyn, Williamsburg and surrounding Brooklyn communities.
Depression can affect motivation, concentration, relationships, sleep, work performance and overall quality of life. For patients who have not experienced enough improvement with traditional antidepressants, a specialized psychiatric evaluation may uncover additional evidence-based options.
NY Ketamine Infusions supports patients from Brooklyn and surrounding New York City communities. Our team reviews treatment history, current symptoms, medical considerations, SPRAVATO® insurance requirements and personal goals before recommending a course of care.
Insurance may cover SPRAVATO® and certain medically necessary behavioral health services for eligible Brooklyn-area patients. Coverage depends on the individual insurance plan, diagnosis, medical necessity and authorization requirements.
Depression is a medical condition that can affect mood, thinking, energy, sleep, appetite, motivation and day-to-day functioning. Symptoms vary from person to person and may continue even after counseling or medication trials.
The National Institute of Mental Health identifies psychotherapy and medication as common treatments for depression, while additional approaches may be considered when standard treatment does not provide adequate relief. National Institute of Mental Health
Treatment-resistant depression generally describes depression that has not improved adequately after appropriate antidepressant treatment. NIMH describes treatment-resistant depression as occurring when a person does not get better after trying at least two antidepressants. NIMH — Depression
A careful evaluation can help determine whether another medication strategy, psychotherapy approach, insurance-covered SPRAVATO®, IV ketamine or another clinically appropriate option should be considered.
Your clinician considers medications, doses, treatment duration, psychotherapy history and prior response.
Sleep, anxiety, medical conditions and diagnostic complexity may influence treatment response.
Recommendations are tailored to symptoms, safety, prior response, goals and insurance requirements.
Insurance policies can differ significantly, even when two patients have coverage through the same carrier. Our team can review potential SPRAVATO® benefits and explain plan requirements before treatment begins whenever possible.
We review symptoms, diagnosis, medications, treatment history, medical history and goals.
Our staff reviews potential benefits and identifies plan-specific authorization requirements.
Supporting documentation may be submitted to the insurer when prior authorization is required.
Your provider discusses the treatment options that may be clinically appropriate for you.
SPRAVATO is the brand name for esketamine, a prescription nasal spray related to ketamine. The FDA currently approves SPRAVATO for treatment-resistant depression in adults, either as monotherapy or together with an oral antidepressant. FDA Prescribing Information
Coverage depends on the individual policy, diagnosis, medical necessity, prior authorization, network requirements and current participation. Listing an insurer does not guarantee coverage.
If you're searching for “SPRAVATO treatment in Brooklyn,” you may expect the provider to have a Brooklyn street address. NY Ketamine Infusions' treatment center is near Brooklyn rather than physically located in Brooklyn.
Our New York City clinic is located at 160 Broadway, 16th Floor, New York, NY 10038 in Lower Manhattan and serves patients traveling from Brooklyn and throughout New York City.
“Where is an experienced SPRAVATO provider near Brooklyn that accepts my insurance?”
Our Lower Manhattan clinic welcomes patients who live or work throughout Brooklyn. Travel time varies by neighborhood, route and transit conditions.
SPRAVATO is administered under healthcare-provider supervision in a certified healthcare setting rather than taken independently at home.
The SPRAVATO REMS requires patients to be observed for at least two hours after treatment while healthcare professionals monitor for effects including sedation, dissociation and respiratory depression. SPRAVATO REMS
Patients also need arrangements for transportation after treatment and should not drive until the following day after a restful sleep, consistent with current FDA prescribing information. FDA Prescribing Information
Esketamine has been evaluated in clinical trials and increasingly in routine clinical practice.
A 2026 systematic review and meta-analysis published in the Journal of Affective Disorders evaluated nine real-world observational studies involving intranasal esketamine for adults with treatment-resistant depression. Researchers reported significant reductions in depressive symptoms, with response and remission rates increasing over time. View the study on PubMed
Individual outcomes vary. Treatment decisions should be based on a clinical evaluation rather than population-level study results alone.
Your initial evaluation is designed to develop a complete picture of your symptoms, health history, previous treatment response and current goals.
Brooklyn residents can request a confidential consultation to discuss insurance-covered SPRAVATO®, treatment-resistant depression and other clinically appropriate treatment options available through our Lower Manhattan clinic.
U.S. Food and Drug Administration. SPRAVATO® prescribing information. Read FDA prescribing information .
National Institute of Mental Health. Depression. Read the NIMH depression guide .
SPRAVATO REMS. Risk Evaluation and Mitigation Strategy requirements for supervised treatment. Visit SPRAVATO REMS .
de Oliveira Lapa C, Viola T, Delfino R, et al. (2026). Systematic review and meta-analysis of intranasal esketamine for treatment-resistant depression. Journal of Affective Disorders. View on PubMed .
